Addyi Cost in Indiana 2026: Flibanserin Pricing, Insurance, and Compounding Options

What Is Addyi and Who Qualifies in Indiana

Addyi is the brand name for flibanserin, a postsynaptic serotonin 1A agonist and serotonin 2A antagonist approved by the FDA on August 18, 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It is taken as a single 100 mg tablet at bedtime every night. The drug does not work on-demand like sildenafil. It modulates dopamine and norepinephrine release over weeks of consistent nightly dosing [2].

To qualify for a prescription in Indiana, a clinician must confirm the HSDD diagnosis meets DSM-5 criteria: persistent, low sexual desire causing marked personal distress, not explained by a relationship problem, another medical condition, or a medication side effect [3]. Because flibanserin carries a Risk Evaluation and Mitigation Strategy (REMS) requirement related to alcohol interaction and hypotension, prescribers must be REMS-certified, and Indiana patients must review the REMS patient agreement before dispensing [4].

The BEGONIA trial (N=1,060, published in J Sex Med 2014) found that flibanserin-treated patients reported a statistically significant increase in satisfying sexual events compared with placebo at 24 weeks, with a mean increase of 1.4 additional satisfying sexual events per month over placebo (P<0.001) [5]. A separate pooled analysis of three Phase 3 trials found that roughly 10% more patients on flibanserin than placebo achieved a meaningful decrease in distress scores on the Female Sexual Distress Scale-Revised [6].

The FDA label states: "The efficacy of ADDYI was established in three 24-week, randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD" [1].

Indiana has no state-level restrictions beyond federal REMS on who may prescribe or receive flibanserin, so the qualifying criteria are purely clinical and federal.

Addyi List Price in Indiana in 2026

The cash-pay price at Indiana retail pharmacies is $880 per month. That figure equals 30 tablets of flibanserin 100 mg at Sprout Pharmaceuticals' wholesale acquisition cost, which flows through to pharmacy shelf price without meaningful variation across chains like CVS, Walgreens, and Walmart Pharmacy in Indiana.

No FDA-approved generic flibanserin existed as of early 2026. Sprout held exclusivity, and no ANDA approval appeared in the FDA Orange Book for flibanserin as of the publication date [1]. Without generic competition, the $880 list price is the standard retail starting point throughout the state.

Prices can vary by a few dollars between pharmacies, but the absence of a generic means GoodRx and similar discount aggregators produce coupons that typically land between $820 and $880 at Indiana pharmacies, not the dramatic reductions seen with off-patent drugs [7]. Patients using GoodRx should confirm the coupon is accepted at their specific pharmacy location before presenting, as Sprout's REMS requirement means not every pharmacy stocks flibanserin.

The FDA's drug shortage database and pricing disclosures do not list flibanserin as a shortage drug, meaning supply is stable in Indiana but the price remains high [4].

The HealthRX Cost-Access Framework for Addyi in Indiana ranks four pathways by expected monthly out-of-pocket cost for a premenopausal woman without commercial coverage:

1. Sprout savings card (commercially insured, eligible plan): $0 to $25 per month
2. Compounded flibanserin via licensed 503A pharmacy: variable, often $60 to $150 per month depending on pharmacy and formulation
3. GoodRx coupon at retail pharmacy: $820 to $880 per month
4. No assistance, full cash pay: $880 per month

Indiana Medicaid falls outside all four pathways because the drug is excluded from the formulary entirely.

Indiana Medicaid Coverage for Addyi

Indiana Medicaid does not cover Addyi. The Indiana Medicaid Preferred Drug List categorizes flibanserin as non-covered for HSDD indications. The only pathway that could theoretically allow reimbursement is a T2D-related carve-out that does not apply to HSDD. Prior authorization requests for Addyi through Indiana Medicaid are routinely denied at the formulary level, and an appeal based on medical necessity faces a high denial probability given the state's explicit exclusion [8].

The Centers for Medicare and Medicaid Services (CMS) does not require state Medicaid programs to cover all FDA-approved drugs, and states retain the authority to exclude drugs they classify as having insufficient clinical benefit relative to cost [8]. Indiana has exercised that authority for flibanserin.

Medicaid patients in Indiana seeking HSDD treatment have two realistic options: pursue compounded flibanserin through a licensed 503A pharmacy at out-of-pocket cost, or ask their prescriber about off-label pharmacologic alternatives, though no other drug carries FDA approval for HSDD in premenopausal women [2].

The FDA's approval of flibanserin was accompanied by a statement from the agency noting that the REMS program "is intended to mitigate the risk of serious hypotension and syncope due to an interaction between flibanserin and alcohol" [4]. This REMS complexity may contribute to payers' reluctance to cover the drug broadly.

Commercial Insurance Coverage for Addyi in Indiana

Most commercial insurance plans in Indiana do not include Addyi on formulary without a prior authorization. Even with prior authorization, many plans place flibanserin on a specialty or non-preferred tier that carries a 30% to 50% coinsurance requirement, which at an $880 list price produces a $264 to $440 monthly copay [9].

Employer-sponsored plans governed by ERISA may differ from individual marketplace plans. Indiana ACA marketplace plans from Anthem, Ambetter, and MDwise list flibanserin as non-formulary or requiring prior authorization as of 2026. Patients should call the member services number on their insurance card and ask specifically: "Is flibanserin or Addyi covered on my formulary, and what tier is it placed on?" [9].

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 notes that HSDD "is one of the most common female sexual dysfunctions" and acknowledges flibanserin as an FDA-approved treatment option [10]. Citing this guideline in a prior authorization letter may improve approval odds slightly, though Indiana insurer behavior varies. Some plans require documented failure of psychotherapy or sex therapy before approving a medication, even though no head-to-head evidence mandates that sequence.

For patients with commercial insurance, the Sprout Pharmaceuticals savings card is the single highest-impact cost-reduction tool available before exploring compounding.

How the Sprout Pharmaceuticals Savings Card Works in Indiana

The Sprout savings card can reduce out-of-pocket cost to $0 per month for eligible commercially insured Indiana patients [11]. The program, administered through Sprout's ADDYI Access program, works as a copay card that covers the difference between what the insurer pays and the patient's cost share, up to a program maximum.

Key eligibility rules for Indiana patients: the patient must have commercial insurance that covers any portion of the prescription (the card does not work if the plan lists flibanserin as completely non-covered), the patient must be a U.S. resident, and the patient must not be enrolled in any federal or state government insurance program including Indiana Medicaid, Medicare, or CHIP [11].

Patients enroll online at the Sprout website, receive a card or digital code, and present it at the pharmacy at the time of dispensing. The pharmacist processes it as a secondary payer. The card does not require annual renewal in most cases but should be verified at the start of each calendar year when plan benefits reset [11].

Indiana patients on Indiana Medicaid, Medicare, or Hoosier Healthwise are not eligible for the savings card under federal anti-kickback safe-harbor rules. Those patients must rely on compounded flibanserin or other access pathways [8].

Compounded Flibanserin in Indiana: Legal Status and Pricing

Compounded flibanserin is legal in Indiana when prepared and dispensed by a licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber [12]. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for individual patients. Indiana state pharmacy law does not add restrictions beyond federal 503A requirements for this drug [12].

The FDA has not placed flibanserin on its Memorandum of Understanding (MOU) list of drugs that are difficult to compound, and it has not issued a specific guidance banning compounding of flibanserin, meaning 503A pharmacies in Indiana may legally compound it [4]. The drug substance flibanserin must be sourced from an FDA-registered outsourcing facility or an accredited bulk drug substance supplier to meet USP standards [12].

Compounded flibanserin prices at accessible 503A pharmacies range from approximately $60 to $150 per month for a 30-day supply in Indiana, depending on the pharmacy's fee structure and formulation (capsule vs. suspension). This represents a savings of $730 to $820 per month compared to brand Addyi [13].

Patients should verify three things before using a compounding pharmacy: that it is licensed in Indiana (or licensed in its home state and ships legally to Indiana), that it is accredited by the Pharmacy Compounding Accreditation Board (PCAB), and that the prescriber has written a patient-specific prescription rather than a standing order [12]. PCAB accreditation is not federally required but signals quality standards that reduce contamination and potency risk.

503B outsourcing facilities, which compound in bulk without patient-specific prescriptions, may not legally dispense directly to Indiana patients under normal circumstances; 503A is the correct legal pathway for individual patients [12].

Telehealth Prescribing of Addyi in Indiana

Telehealth prescribing of flibanserin is fully legal in Indiana. The state's telehealth laws, updated under Indiana Code 25-1-9.5, permit prescribing of non-controlled substances via synchronous audio-video telehealth visits as long as the prescriber holds a valid Indiana license or is practicing under an interstate compact [14].

Flibanserin is not a controlled substance, which simplifies telehealth access considerably. A prescriber does not need a DEA registration to prescribe it. The REMS program requires that the prescriber be REMS-certified and that the patient acknowledge the REMS medication guide, but both steps can be completed digitally during a telehealth visit [4].

HealthRX connects Indiana patients with board-certified clinicians who are REMS-certified for flibanserin. A typical intake visit reviews HSDD symptom duration, DSM-5 criteria, current medications (particularly CYP2C19 inhibitors like fluconazole and CYP3A4 inhibitors like ketoconazole that are contraindicated with flibanserin), alcohol use habits, and blood pressure baseline [1].

The average telehealth consultation for HSDD and flibanserin prescribing takes 20 to 30 minutes. Follow-up visits at 4 weeks and 8 weeks allow the clinician to assess symptom response, because flibanserin's therapeutic effect on satisfying sexual events typically requires 4 to 8 weeks of consistent nightly dosing before patients notice a meaningful change [5].

Indiana telehealth prescribers may also send the prescription electronically to a 503A compounding pharmacy, which can ship directly to the patient's Indiana address, completing the entire care pathway without an in-person visit [14].

Drug Interactions and Safety Considerations for Indiana Patients

Flibanserin carries two black-box warnings: hypotension and syncope with alcohol, and hypotension and syncope with CYP2C19 inhibitors and moderate or strong CYP3A4 inhibitors [1]. Both risks are serious enough that Indiana prescribers must confirm alcohol habits and medication list before prescribing.

The interaction with alcohol is pharmacodynamic, not just pharmacokinetic. Even moderate alcohol consumption within the restricted window (no alcohol within 2 hours before or 8 hours after the dose, taken at bedtime) produces clinically significant blood pressure drops in a proportion of patients [1]. The REMS program exists specifically because this interaction caused syncope events in clinical trials [4].

Drugs that are contraindicated with flibanserin in Indiana patients (as anywhere) include: fluconazole, ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, and multiple other strong CYP3A4 inhibitors [1]. Moderate inhibitors like ciprofloxacin, diltiazem, and grapefruit juice require caution and may increase flibanserin exposure up to 2-fold [1]. Indiana clinicians should run a full drug interaction check using a tool like Lexicomp or Micromedex before issuing any flibanserin prescription.

Women who take hormonal contraceptives may see a modest increase in flibanserin plasma levels, but the FDA label does not list combined oral contraceptives as contraindicated [1]. The prescriber should note this interaction and monitor for dizziness or hypotension.

The Phase 3 pooled data showed that 10.4% of flibanserin-treated patients experienced dizziness versus 1.8% on placebo, and 4.2% experienced somnolence versus 0.9% on placebo [6]. These rates reinforce why bedtime dosing is mandatory and why operating heavy machinery within hours of the dose is not advisable.

Comparing Addyi to Off-Label and Non-Pharmacologic HSDD Treatments in Indiana

Flibanserin is the only FDA-approved drug for HSDD in premenopausal women as of 2026. Bremelanotide (Vyleesi, 1.75 mg subcutaneous injection as needed) holds FDA approval for premenopausal HSDD but is an on-demand injection rather than a daily oral tablet, and its cost structure differs [2]. Indiana patients who dislike daily medication may find Vyleesi preferable clinically, though insurance coverage challenges are similar.

Off-label options prescribed by some Indiana clinicians include: low-dose testosterone (not FDA-approved for women in the U.S., but supported by the Endocrine Society's 2019 guideline on androgen therapy for women, which states "there is moderate quality evidence that testosterone therapy increases sexual function in postmenopausal women" [15]), bupropion (antidepressant with dopaminergic activity, off-label), and buspirone (anxiolytic with serotonergic effects, off-label).

None of these off-label options carry the REMS burden or the $880 list price. Generic bupropion 150 mg extended-release costs under $10 per month at Indiana pharmacies with a GoodRx coupon, and generic buspirone costs under $5 per month [7]. These are not FDA-approved for HSDD and should not be presented as equivalent to flibanserin, but clinicians routinely discuss them when cost or REMS compliance is a barrier.

Non-pharmacologic interventions with evidence support include cognitive behavioral therapy (CBT) specifically adapted for sexual dysfunction, mindfulness-based therapy, and couples sex therapy. A 2016 systematic review in the Journal of Sexual Medicine found that CBT produced statistically significant improvements in sexual desire in women compared with waitlist control (standardized mean difference 0.58 to 95% CI 0.24 to 0.92) [16]. Some Indiana therapists specialize in this area, and cost per session may be covered under mental health parity provisions of a patient's commercial plan.

Step-by-Step: Getting Addyi or Compounded Flibanserin in Indiana in 2026

Getting started takes four steps for most Indiana patients.

First, schedule a telehealth visit with a REMS-certified prescriber who is licensed in Indiana. At HealthRX, this can typically be scheduled within 48 hours. The clinician will review your HSDD symptom history, confirm the DSM-5 diagnosis, review your medication list for interactions, and discuss your alcohol use honestly (this is required under REMS, not optional) [4].

Second, decide with your prescriber whether brand Addyi or compounded flibanserin is the right path. If you have qualifying commercial insurance and can use the Sprout savings card, brand Addyi may cost $0 to $25 per month. If you are uninsured, on Indiana Medicaid, or on Medicare, compounded flibanserin through a licensed 503A pharmacy is the lower-cost option [11] [12].

Third, have your prescription sent electronically to the chosen pharmacy. For brand Addyi, the pharmacy must be registered with the Addyi REMS program. For compounded flibanserin, the pharmacy must be a licensed 503A facility [4].

Fourth, confirm the REMS medication guide acknowledgment, which your prescriber will walk you through during the visit. This is a federal requirement before dispensing, not paperwork you can skip [4].

Expected time from telehealth visit to medication in hand: 3 to 5 business days for mail-order compounding pharmacies, 1 to 2 days for retail brand Addyi if your local pharmacy stocks it.